Literature DB >> 15592841

Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9.

Tomoki Ito1, Yui-Hsi Wang, Yong-Jun Liu.   

Abstract

Plasmacytoid dendritic cell (pDC) precursors, also called type I IFN (alpha/beta/omega)-producing cells (IPCs), are the key effectors in the innate immune system because of their extraordinary capacity to produce type I IFNs against microbial infection, particularly viral infection. In contrast to myeloid DCs, human pDC/IPCs selectively express Toll-like receptor (TLR) 7 and TLR9 within the endosomal compartment. These receptors are specifically designed to recognize the nucleoside-based products derived from RNA viruses and DNA viruses. Therefore, this expression profile potentially enables pDC/IPCs to sense a variety of viruses. Stimulation of TLR7 or TLR9 leads to type I IFN responses through the MyD88 pathway. Thus, pDC/IPCs may play a central role in host defense against viral infection through the TLR7 and TLR9 system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592841     DOI: 10.1007/s00281-004-0180-4

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  64 in total

1.  Expression of pTalpha mRNA in a committed dendritic cell precursor in the human thymus.

Authors:  P C Res; F Couwenberg; F A Vyth-Dreese; H Spits
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

2.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 3.  Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.

Authors:  Y J Liu
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

Review 4.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells.

Authors:  F Re; J L Strominger
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

6.  Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2.

Authors:  R Schwandner; R Dziarski; H Wesche; M Rothe; C J Kirschning
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

7.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

8.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

9.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs.

Authors:  Tomoki Ito; Ryuichi Amakawa; Muneo Inaba; Toshiyuki Hori; Maiko Ota; Kengo Nakamura; Masashi Takebayashi; Michihiko Miyaji; Tomoo Yoshimura; Kayo Inaba; Shirou Fukuhara
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

View more
  86 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.

Authors:  Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski
Journal:  J Neuroimmunol       Date:  2019-05-20       Impact factor: 3.478

Review 3.  Immunoregulation of dendritic cells.

Authors:  Mark A Wallet; Pradip Sen; Roland Tisch
Journal:  Clin Med Res       Date:  2005-08

Review 4.  Vaccines: all things considered.

Authors:  Ken S Rosenthal; Daniel H Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 5.  Dendritic cells at the oral mucosal interface.

Authors:  C W Cutler; R Jotwani
Journal:  J Dent Res       Date:  2006-08       Impact factor: 6.116

Review 6.  The role of type I interferon production by dendritic cells in host defense.

Authors:  P Fitzgerald-Bocarsly; D Feng
Journal:  Biochimie       Date:  2007-05-08       Impact factor: 4.079

Review 7.  Toll-like receptor-independent triggering of dendritic cell maturation by viruses.

Authors:  Carolina B López; Jacob S Yount; Thomas M Moran
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads.

Authors:  Jian Zhou; Yuancheng Huang; Deying Tian; Dong Xu; Miao Chen; Huiling Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 9.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

10.  The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus.

Authors:  Hsuen-Wen Chang; Yen-Hung Chow; Pele Chong; Charles Sia
Journal:  Rev Diabet Stud       Date:  2007-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.